Drug Database
OL

olopatadine (Patanase / Patanase)

✓ Approved

Novartis AG · HRH1 · 小分子

什么是 olopatadine?

olopatadine 是一种小分子,由Novartis AG研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

商品名Patanase, Patanase
公司Novartis AG
药物类别小分子
分子靶点HRH1
给药途径Inhaled
状态Approved

作用机制

分子靶点

olopatadine 作用于 1 个分子靶点:

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

olopatadine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersSeasonal allergy✓ Approved
Eye disordersConjunctivitis allergicBLA/NDA

相关研究文献

PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis.

Li Caiju C, Gao Yuying Y, Wei Lijuan L

Allergic conjunctivitis (AC) affects 15%-40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents. Registered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed. Nineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate. Topical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.

PMID 43042078
阅读全文 →
PubMedPharmaceutical development and technology2026-11-17

Thermosensitive in situ nasal gel of Magnoliae Flos-Centipeda Herba for allergic rhinitis: preparation, characterization, and in vivo pharmacodynamics and pharmacokinetics studies.

Ma Yuxuan Y, Wang Zelong Z, Kang Baorong B, Xia Qingyun Q et al.

Magnoliae Flos and Centipeda Herba are classic herbal medicines for allergic rhinitis in traditional Chinese medicine, yet conventional nasal drops suffer from rapid clearance by nasal mucocilia, leading to limited nasal residence time. Herein, a thermosensitive in situ gel loaded with Magnoliae Flos and Centipeda Herba extract (MFCH-TGL) was fabricated to achieve prolonged, safe intranasal delivery. The gel matrix was composed of 17% (w/v) poloxamer 407 and 1% (w/v) poloxamer 188, incorporated with 2.3% (w/v) alcoholic extract and 0.5% (v/v) volatile oil of MFCH. We systematically characterized sol-gel transition performance, rheological behavior, in vitro release and ex vivo nasal permeation, and further assessed anti-allergic pharmacodynamics in BALB/c mice as well as nasal pharmacokinetics in SD rats. The formulation exhibited a sol-gel transition at 33.5 °C within 17 s, with 40.6 ± 1.97% cumulative nasal permeation over 8 h. Medium-dose MFCH-TGL markedly reduced OVA-specific IgE (8.28 ± 1.64, P < 0.01) compared with the allergic model group (12.55 ± 1.86). Moreover, the gel displayed 1.46-fold longer half-life and 1.52-fold longer mean residence time than the MFCH aqueous solution. This thermosensitive in situ gel presents promising intranasal application potential, offering a feasible formulation strategy for traditional Chinese medicine against allergic rhinitis.

PMID 43042950
阅读全文 →
PubMedRSC advances2026-11-17

Spray-pyrolyzed Co-doped CeO2 thin films for composition-tunable third-order nonlinear optics and optical limiting.

Poonja Rahul S RS, Surabhi Srivathsava S, Girish Santhosh S, Gummagol Neelamma B NB et al.

Cobalt-doped cerium oxide (Co-CeO2) thin films (0, 10, 20, and 30% Co) were fabricated on glass substrates via air-blast spray pyrolysis and annealed at 350 °C to examine composition-dependent linear and third-order nonlinear optical (NLO) responses. X-ray diffraction and whole-pattern refinement were consistent with retention of the cubic fluorite CeO2 lattice across all compositions with progressive peak broadening indicating increased structural disorder at higher Co loadings. Scanning electron microscopy showed a morphological transition from a dense nanogranular surface to fine-grained, microcracked domain networks with energy-dispersive X-ray (EDX) mapping confirming homogeneous Ce, O, and Co distribution. X-ray photoelectron spectra indicated changes in near-surface oxygen and cation chemical environments. Co incorporation red-shifted the optical absorption edge, reducing the direct and indirect bandgaps from 3.32 and 2.87 eV (direct) to 2.79 and 2.43 eV (indirect), correspondingly, while the Urbach energy expanded from 1.24 to 1.74 eV, confirming enhanced sub-bandgap tail states. Open-aperture (OA) Z-scan measurements (at 532 nm) revealed reverse saturable absorption (RSA) with the nonlinear absorption coefficient increasing from 6.6 × 10-2 to 16.2 × 10-2 cm W-1 from undoped to 30% Co films. Closed-aperture (CA) measurements demonstrated positive nonlinear refraction, where the 20% Co film achieved the maximum nonlinear refractive response and total third-order susceptibility (χ (3)). Conversely, the 30% Co film yielded the highest absorptive nonlinearity and the lowest optical limiting threshold (1.80 kJ cm-2). These results establish composition-selective functionality in spray-pyrolyzed Co-CeO2 thin films: 20% Co optimizes phase modulation and overall, third-order NLO response, whereas 30% Co is ideal for absorption-driven optical limiting.

PMID 43042316
阅读全文 →
PubMedTurkish archives of pediatrics2026-11-17

High Flow Nasal Cannula: Weaning Protocol.

Agarwal Pulkit P

PMID 43041044
阅读全文 →
PubMedJournal of investigational allergology & clinical immunology2026-11-17

Beyond Serum Biomarkers: Toward Cellular Phenotyping of Chronic Rhinosinusitis With Nasal Polyps.

Gelardi Matteo M

PMID 43042770
阅读全文 →
PubMedJournal of intensive medicine2026-11-17

Revisiting prophylactic high-flow nasal oxygen therapy after cardiac surgery: The unilluminated corners.

Yu Weijie W, Xu Jingyuan J

PMID 43041630
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多olopatadine